- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfContingentLiabilitiesLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount that counterparty can elect to receive in lieu of warrants if change of control transaction occurs.

+ References

No definition available.

+ Details

Name:	prqr_AmountThatCounterpartyCanElectToReceiveInLieuOfWarrantsIfChangeOfControlTransactionOccurs
Namespace Prefix:	prqr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Funding received under agreement

+ References

No definition available.

+ Details

Name:	prqr_FundingReceivedUnderAgreement
Namespace Prefix:	prqr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

No definition available.

+ Details

Name:	prqr_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
Namespace Prefix:	prqr_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

No definition available.

+ Details

Name:	prqr_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix:	prqr_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Maximum grant receivable for additional phase of the project.

+ References

No definition available.

+ Details

Name:	prqr_MaximumGrantReceivableForAdditionalPhaseOfProject
Namespace Prefix:	prqr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Maximum grant receivable for the initial phase of the project.

+ References

No definition available.

+ Details

Name:	prqr_MaximumGrantReceivableForInitialPhaseOfProject
Namespace Prefix:	prqr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Noncurrent research and development commitments, maturity.

+ References

No definition available.

+ Details

Name:	prqr_NoncurrentResearchAndDevelopmentCommitmentsMaturity
Namespace Prefix:	prqr_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of installments of one-time milestone payment due to counterparty following first commercial sale of product.

+ References

No definition available.

+ Details

Name:	prqr_NumberOfInstallmentsOfOneTimeMilestonePaymentDueToCounterpartyFollowingFirstCommercialSaleOfProduct
Namespace Prefix:	prqr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of tranches through which amount that counterparty can elect to receive in lieu of warrants if change of control transaction occurs will be set off against the milestone payment.

+ References

No definition available.

+ Details

Name:	prqr_NumberOfTranchesThroughWhichAmountThatCounterpartyCanElectToReceiveInLieuOfWarrantsIfChangeOfControlTransactionOccursWillBeSetOffAgainstMilestonePayment
Namespace Prefix:	prqr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

One-time milestone payment due to counterparty following first commercial sale of product.

+ References

No definition available.

+ Details

Name:	prqr_OneTimeMilestonePaymentDueToCounterpartyFollowingFirstCommercialSaleOfProduct
Namespace Prefix:	prqr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Payment term from receipt of licensing revenue of royalties payable to counterparty if entity licenses out the program.

+ References

No definition available.

+ Details

Name:	prqr_PaymentTermFromReceiptOfLicensingRevenueOfRoyaltiesPayableToCounterpartyIfEntityLicensesOutProgram
Namespace Prefix:	prqr_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Payment term of first installment of one-time milestone payment due to counterparty following first commercial sale of product.

+ References

No definition available.

+ Details

Name:	prqr_PaymentTermOfFirstInstallmentOfOneTimeMilestonePaymentDueToCounterpartyFollowingFirstCommercialSaleOfProduct
Namespace Prefix:	prqr_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of earn-out payments for milestones and sales to be received

+ References

No definition available.

+ Details

Name:	prqr_PercentageOfEarnOutPaymentsForMilestonesAndSalesToBeReceived
Namespace Prefix:	prqr_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of royalties payable to counterparty if entity licenses out the program.

+ References

No definition available.

+ Details

Name:	prqr_PercentageOfRoyaltiesPayableToCounterpartyIfEntityLicensesOutProgram
Namespace Prefix:	prqr_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The cash outflow from repayments of previously received funding

+ References

No definition available.

+ Details

Name:	prqr_RepaymentsOfPreviouslyReceivedFunding
Namespace Prefix:	prqr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of future research and development expenditures that the entity is committed to make.

+ References

No definition available.

+ Details

Name:	prqr_ResearchAndDevelopmentCommitments
Namespace Prefix:	prqr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of future research and development expenditures related to ongoing clinical trial that the entity is committed to make.

+ References

No definition available.

+ Details

Name:	prqr_ResearchAndDevelopmentCommitmentsRelatedToOngoingClinicalTrial
Namespace Prefix:	prqr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Warrants, economic lifetime

+ References

No definition available.

+ Details

Name:	prqr_WarrantsEconomicLifetime
Namespace Prefix:	prqr_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	prqr_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=prqr_ClinicalSupportAgreementWithFoundationFightingBlindnessFfbMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	prqr_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=prqr_ResearchAndDevelopmentAgreementWithRettSyndromeResearchTrustMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=prqr_UltevursenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies - Clinical support agreements (Details)		1 Months Ended	12 Months Ended	95 Months Ended
	Dec. 05, 2024 USD ($) installment $ / shares shares	Dec. 31, 2023 EUR (€)	Dec. 31, 2025 EUR (€)	Dec. 31, 2025 EUR (€)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 EUR (€)	Jan. 04, 2024 EUR (€)
Commitments and Contingencies
Research and development commitments			€ 8,566,000	€ 8,566,000		€ 9,828,334
Research and development expenditures			1,972,000	1,972,000
Clinical support agreement with Foundation Fighting Blindness (FFB)
Commitments and Contingencies
Funding received under agreement				6,300,000	$ 6,800,000
Repayments of previously received funding		€ 1,100,000
Research and development agreement with RSRT
Commitments and Contingencies
Maximum grant receivable for the initial phase of the project							€ 1,015,000
Maximum grant receivable for additional phase of the project \| $	$ 8,150,000
Number of installments of one-time milestone payment due to counterparty following first commercial sale of product \| installment	4
Payment term of first installment of one-time milestone payment due to counterparty following first commercial sale of product	60 days
Warrants, economic lifetime	7 years
Number of shares that can be purchased with issued warrants \| shares	2,144,772
Exercise price of warrants \| $ / shares	$ 3.73
Amount that counterparty can elect to receive in lieu of warrants if change of control transaction occurs \| $	$ 16,300,000
Number of tranches through which amount that counterparty can elect to receive in lieu of warrants if change of control transaction occurs will be set off against the milestone payment \| installment	4
Percentage of royalties payable to counterparty if entity licenses out the program	10.00%
Payment term from receipt of licensing revenue of royalties payable to counterparty if entity licenses out the program	60 days
Less than 1 year
Commitments and Contingencies
Research and development commitments			8,150,000	8,150,000
Research and development expenditures			€ 1,721,000	€ 1,721,000
Minimum
Commitments and Contingencies
Noncurrent research and development commitments, maturity			2 years
Minimum \| ultevursen
Commitments and Contingencies
Percentage of earn-out payments for milestones and sales to be received			5.00%	5.00%
Maximum
Commitments and Contingencies
Noncurrent research and development commitments, maturity			5 years
Maximum \| Research and development agreement with RSRT
Commitments and Contingencies
One-time milestone payment due to counterparty following first commercial sale of product \| $	$ 40,750,000
Maximum \| ultevursen
Commitments and Contingencies
Percentage of earn-out payments for milestones and sales to be received			10.00%	10.00%